Incidence of neural tube defects in Ontario, 1986–1999

Enza Gucciardi,* Mary-Anne Pietrusiak,† Donna L. Reynolds,† Jocelyn Rouleau‡

Abstract

Background: Prenatal screening and the promotion of folic acid intake could affect the incidence of neural tube defects (NTDs). We examined trends in the total NTD incidence, as detected in live births, stillbirths and therapeutic abortions, from 1986 to 1999 in Ontario.

Methods: To capture cases of NTDs we used data from the Canadian Congenital Anomalies Surveillance System and hospital data on therapeutic abortions. We calculated the total incidence of NTDs by combining the numbers of NTDs occurring in live births, stillbirths and therapeutic abortions.

Results: The total NTD incidence rate increased from 11.7 per 10 000 pregnancies in 1986 to 16.2 per 10 000 in 1995, and it subsequently decreased to 8.6 per 10 000 by 1999. The NTD birth rate (live births and stillbirths) decreased from 10.6 per 10 000 births in 1986 to 5.3 per 10 000 in 1999. The rate of therapeutic abortions with an NTD or hydrocephalus rose from 17.5 per 10 000 abortions in 1986 to 50.7 per 10 000 in 1995 and fell to 28.7 per 10 000 abortions in 1999.

Interpretation: The total NTD incidence rate increased from 1986 to 1995, probably because of increased prenatal screening and better detection of NTDs. The decline from 1995 to 1999 may have been due to increased folic acid intake among women at the time of conception.

Neural tube defects (NTDs) result in congenital malformations of the nervous system and may lead to spontaneous abortion, stillbirth, death in early infancy or a lifetime of disability. Studies of congenital anomalies in Alberta, Manitoba and Ontario showed a significant decline in NTD birth prevalence between 1979 and 1993. During that time, there was also an increased use of prenatal screening programs, which offer women and their families the option of terminating a pregnancy at high risk of having an NTD. Since a large proportion of NTD cases are detected prenatally through routine screening and may result in a therapeutic abortion, the NTD birth prevalence may be substantially reduced.

Canadian, Australian, European and American studies have reported decreases in the birth prevalence of NTDs in their populations over the past decades, with most reporting either no change or a decline in total prevalence rates.

Surveillance systems that monitor only births affected by NTDs underestimate the overall incidence since they miss cases that are detected prenatally and terminated during pregnancy. Birth incidence rates may reflect differences in screening practices and diagnostic standards rather than the true incidence of NTD cases.

The Canadian Congenital Anomaly Surveillance System (CCASS) estimates birth defect incidence among live births and stillbirths, but it does not capture cases that are spontaneously or therapeutically aborted. Therefore we report the total incidence of NTDs in Ontario from 1986 to 1999 by combining data on live births and stillbirths with hospital data on therapeutic abortions.

Methods

The CCASS estimates the incidence of numerous congenital anomalies using hospital administration data from the Canadian Institute for Health Information (CIHI). CCASS
methodologies are described elsewhere. The CCASS provided
us with the number of NTD cases among live births and still-
births occurring in Ontario hospitals from 1986 to 1999 as well as
the total number of live births and stillbirths. Data on live births
include data for infants admitted to hospital in the first year of life
because of congenital anomalies, since not all anomalies are de-
tected at birth. Health Canada, the administrator of the CCASS,
applies an algorithm to remove duplicate records. We also ana-
lyzed the type of NTD, whether spina bifida (includes spina bifida
with hydrocephalus), anencephaly or encephalocele.

Data on therapeutic abortions with an NTD or hydrocephalus
occurring from 1986 to 1999 in Ontario were also based on CIHI
hospital administration data, which we obtained through the Cen-
tral East Health Information Partnership and the Ontario Min-
istry of Health and Long-Term Care. We defined the termina-
tion of pregnancies with NTDs or hydrocephalus as legally
induced abortions performed in hospital (International Classifica-
tion of Diseases, ninth revision [ICD-9] code 635) on an in-pa-
tient or day surgery basis in which a central nervous system mal-
formation was identified in the fetus as anencephaly,
hydrocephalus or spina bifida (ICD-9 code 655.0). Hydro-
cephalus may have been included in the ICD-9 code because it is
more prevalent than encephalocele and is a common manifesta-
tion in anencephaly and spina bifida cases. Because we could
not differentiate hydrocephalus from the NTDs in these data, we
included hydrocephalus birth incidence rates in the analysis. The
Ontario Ministry of Health and Long-Term Care also gave us the
total number of therapeutic abortions performed in hospital. We
did not include therapeutic abortions conducted in free-standing
abortion clinics. We also made no attempt to capture data on
spontaneous NTD abortions.

We computed the total NTD incidence rate by combining live
births, stillbirths and therapeutic abortions in both numerator and
denominator. The birth incidence rate included live births and still-
births only. Appendix 1 summarizes how we calculated the rates.

Results

A total of 3207 NTDs occurred in Ontario from 1986 to
1999: 1503 detected in live births, 425 in stillbirths and
1279 in therapeutic abortions. The total NTD incidence
rate increased by 38% from 1986 to 1995, from 11.7 to
16.2 per 10 000 pregnancies (p < 0.001); however, the rate
dropped by 47% from 1995 to 1999, to 8.6 per 10 000
pregnancies (p < 0.001) (Fig. 1). The NTD birth incidence
rate decreased by 50% from 1986 to 1999, from 10.6 to 5.3
per 10 000 births (p < 0.001) (Fig. 1); overall, 78% of the
affected births were live births and 22% were stillbirths.

There was no significant change in the hydrocephalus birth
rate during the study period (Fig. 1).

The rate of NTDs in live births declined by 50% during
the study period, from 8.6 per 10 000 live births in 1986 to
4.3 per 10 000 live births in 1999 (p < 0.001) (Fig. 2). Most of
the live births were cases of spina bifida (75%), the remain-
der being encephalocele (15%) and anencephaly (11%). The
rate of spina bifida in live births decreased by 52% over time
(p < 0.001); the rates of anencephaly and encephalocele de-
creased by 42% (p < 0.002) and 45% (p = 0.002) respectively.

On average, 3.2% of all stillbirths were diagnosed with an
NTD, as compared with 0.1% of all live births. The rate of
stillbirths with an NTD dropped by 53%, from 33.6 per
1000 stillbirths in 1986 to 15.9 per 1000 in 1999 (p < 0.001)
(Fig. 3). In contrast to live births, the most common NTD

![Fig. 1: Total incidence rates of neural tube defects (NTDs) and birth incidence rates of NTDs and hydrocephalus in Ontario, 1986–1999.](image1)

![Fig. 2: Incidence rates of NTDs in live births, by type of NTD.](image2)

![Fig. 3: Incidence rates of NTDs in stillbirths, by type of NTD.](image3)
among stillbirths was anencephaly (57%); spina bifida accounted for 35% and encephalocele for 7% of affected stillbirths. Although stillbirth rates for anencephaly decreased significantly (by 60%, p < 0.001), spina bifida rates showed no significant change. Statistical tests for trend were not analyzed for encephalocele because of the small number of cases.

From 1986 to 1995 the rate of therapeutic abortions in which an NTD or hydrocephalus was detected rose 190%, from 17.5 to 50.7 per 10 000 abortions (p < 0.001). By 1999 it had fallen by 43%, to 28.7 per 10 000 abortions (p < 0.001) (Fig. 4). In 1999 the distribution of total NTDs was 42% live births, 10% stillbirths and 47% therapeutic abortions (Fig. 5). This was a shift from 1986, when the distribution was 61%, 15% and 25% respectively.

**Interpretation**

We found that NTD rates detected at birth decreased from 1986 to 1999, with most of the decrease occurring after 1995. The rate of therapeutic abortions with an NTD or hydrocephalus increased from 1986 to 1995 but decreased from 1995 to 1999. In 1986 the ratio of NTD-affected births to therapeutic abortions was 3:1, as compared with 1:1 in 1999.

The increase in the rate of therapeutic abortions with an NTD or hydrocephalus and the subsequent decrease after 1995 may be explained by both artifactual and real influences. Artifactual explanations relate to data quality. The data on therapeutic abortions were problematic because the ICD-9 code 655.0 grouped anencephaly, spina bifida and hydrocephalus together rather than the standard NTD classification of anencephaly, spina bifida and encephalocele. Because the ICD-9 code included hydrocephalus rather than encephalocele, we may have calculated inflated rates of NTD-affected therapeutic abortions. However, the birth incidence of hydrocephalus remained constant over the 14-year study period, which may indicate a similar trend for the incidence of therapeutic abortions affected by hydrocephalus.

We examined data on only therapeutic abortions performed in hospitals owing to the lack of data on those with NTD or hydrocephalus performed in free-standing abortion clinics. It is unlikely that clinics perform many NTD-affected therapeutic abortions since the detection of NTDs usually occurs between 16 and 20 weeks' gestation.

An important consideration for data quality is case ascertainment, particularly if detection or reporting has changed over time. The CCASS uses hospital separation data to identify anomalies and determines the number of individual cases by internally linking the records to remove duplicates. Personal identifiers are removed from the records, which necessitates a probabilistic melding process that links the individual records using variables such as sex, date of birth and postal code. The process depends on complete information. Since NTDs are serious anomalies, few cases would escape hospitalization; however, it may be possible that hospital data have become more complete in recent years, resulting in more accurate identification of duplicates. The completeness of therapeutic abortion data, also based on hospital records, is more difficult to assess. In-depth research through methods such as chart review could provide insight into the quality of these data.

There are 2 recent influences that may explain the trends in NTD incidence rates: prenatal screening and use of folic acid. Prenatal screening is likely the main reason for the decreased rates of live births with an NTD and the increased rates of therapeutic abortions with NTD or hydrocephalus before 1996. The decrease after 1995 is consistent with the release of recommendations for folic acid use before conception by women of child-bearing years and the provision of related preconception education. In the late 1990s initiatives to promote folic acid use expanded, including activities by boards of health and fortification of flour and pasta in Canada in January 1998. It has been suggested that a decrease of 30% to 40% in the incidence of NTDs could be expected even with relatively low levels of fortification.

Assessments of folic acid intake or serum folate concentrations would strengthen conclusions from this study. Additional research is needed to explore the effectiveness of strategies to promote folic acid use such as preconception...
education, supplementation, and fortification of flour and pasta. Standardized reporting of NTDs, including cases in therapeutic abortions, is needed to ensure that rates are interpreted correctly.

Competing interests: None declared.

Contributors: Ms. Gucciardi conducted the initial study as a practicum project for her MHS in Community Health and Epidemiology; she conducted the literature review, collected and interpreted the data, and drafted the article. Ms. Pietersz-Buis supervised the practicum, contributed to the data collection and analysis, reviewed the methodology and contributed to the writing and revising of the article. Dr. Reynolds provided clinical input, reviewed the methodology, interpreted the data and edited the article. Mr. Rouleau provided data from the Canadian Congenital Anomalies Surveillance System, contributed to the data interpretation and reviewed the article.

Acknowledgements: We thank the Central East Health Information Partnership for funding and assisting us with this project. We also appreciate the assistance of the Maternal Serum Screening Program at North York General Hospital, the Ontario Ministry of Health and Long-Term Care and Health Canada.

References


Appendix 1: Methods used to calculate incidence rates of neural tube defects (NTDs) and hydrocephalus

<table>
<thead>
<tr>
<th>Incidence rate</th>
<th>Method of calculation</th>
</tr>
</thead>
<tbody>
<tr>
<td>NTDs Total (per 10 000 pregnancies)</td>
<td>No. of live births* and stillbirths with NTDs plus therapeutic abortions with NTDs or hydrocephalus + total no. of live births and stillbirths plus total no. of therapeutic abortions performed in hospital × 10 000</td>
</tr>
<tr>
<td>Birth (per 10 000 births)</td>
<td>No. of live births* and stillbirths with NTDs + total no. of live births and stillbirths × 10 000</td>
</tr>
<tr>
<td>Live birth (per 10 000 live births)</td>
<td>No. of live births* with NTDs + total no. of live births × 10 000</td>
</tr>
<tr>
<td>Stillbirth (per 1000 stillbirths)</td>
<td>No. of stillbirths with NTDs + total no. of stillbirths × 1000</td>
</tr>
<tr>
<td>Hydrocephalus (per 10 000 births)</td>
<td>No. of live births* and stillbirths with hydrocephalus + total no. of live births and stillbirths × 10 000</td>
</tr>
<tr>
<td>NTDs or hydrocephalus in therapeutic abortions (per 10 000 abortions)</td>
<td>No. of therapeutic abortions with NTDs or hydrocephalus + total no. of therapeutic abortions performed in hospital × 10 000</td>
</tr>
</tbody>
</table>

*Includes infants up to 1 year of age admitted to hospital.